While we cannot exclude localized KP alterations in most-affected brain regions, whose signal is diluted when examining CSF or plasma, based on the results obtained in this study, it is difficult to support targeting the KP pathway (e.g., with kynurenine monooxygenase inhibitor, CHDI-340246)12 as a therapy for HD. Here, NPPA is linked to Huntington disease.